# The wake of addiction: Pharmacological strategies for sleep disturbances in stimulant use disorders, a systematic review. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/sleep-disturbances-stimulant-use-disorders-treatment-systematic-review/ > **Published:** 2026-04-27T18:27:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:00:46-04:00 > **Clinical Summary:** Systematic review examines pharmacological treatments for sleep disturbances in cocaine and methamphetamine use disorders, identifying 18 studies with evidence- --- CED Clinical Relevance  #70Notable Clinical Interest Evidence Brief | CED Clinic[Systematic review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/) identifies limited but promising pharmacological options for treating sleep disturbances in cocaine and methamphetamine use disorders. Sleep DisordersStimulant Use DisorderPharmacotherapy[Systematic Review](https://cedclinic.com/cannabinoid-safety-efficacy-mental-health-study/)[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) Systematic review identifies limited but promising pharmacological options for treating sleep disturbances in cocaine and methamphetamine use disorders. What This Study Teaches Us This systematic review establishes that sleep disturbances in stimulant use disorders have been studied with pharmacological interventions, though the evidence base remains limited with only 18 qualifying studies. The review methodology appears rigorous, employing PRISMA guidelines and demonstrating good interrater reliability for bias assessment. Why This Matters Sleep disturbances are common and clinically significant complications in stimulant use disorders that can perpetuate addiction cycles and complicate recovery. Having a systematic evaluation of pharmacological treatment options provides clinicians with evidence-based guidance for addressing this challenging aspect of stimulant use disorder management. Study Snapshot Study Type Systematic Review Population Adults with cocaine use disorder (CUD) or methamphetamine use disorder (MUD), n=678 across 18 studies Intervention Various pharmacological treatments for sleep disturbances Comparator Control conditions varied by included study Primary Outcome Night-time sleep outcomes measured with rigorous assessment tools Key Finding 18 studies met inclusion criteria with good interrater reliability for bias assessment Journal Drug and Alcohol Dependence Year 2025 Clinical Bottom Line While pharmacological interventions for sleep disturbances in stimulant use disorders have been studied, the limited number of qualifying studies suggests this remains an area with significant evidence gaps. The rigorous methodology of this review provides a foundation for understanding current treatment options and identifying research priorities. What This Paper Does Not Show The abstract does not reveal which specific pharmacological interventions were studied, their relative efficacy, or safety profiles. Without access to the full results, we cannot determine which medications showed benefit or how clinically meaningful any improvements were. Where This Paper Deserves Skepticism With only 18 studies across two distinct stimulant use disorders and a total population of 678 participants, the evidence base appears relatively small. The heterogeneity of study designs, populations, and interventions likely limits the ability to draw definitive conclusions about optimal treatment approaches. Dr. Caplan's Take Sleep problems in stimulant use disorders are real and disruptive, but I’m not surprised the evidence base is thin—these are challenging populations to study systematically. Until I see the actual results, I remain cautious about changing practice based on this review alone, though it’s valuable to know what evidence exists. What a Careful Reader Should Take Away This systematic review represents a methodologically sound attempt to synthesize evidence on pharmacological sleep interventions in stimulant use disorders. However, the limited number of studies highlights the need for more research rather than providing clear clinical guidance at this point. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20The%20wake%20of%20addiction%3A%20Pharmacological%20strategies%20for%20sleep%20disturbances%20in%20stimulant%20use%20disorders%2C...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fsleep-disturbances-stimulant-use-disorders-treatment-systematic-review%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fsleep-disturbances-stimulant-use-disorders-treatment-systematic-review%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20The%20wake%20of%20addiction%3A%20Pharmacological%20strategies%20for%20sleep%20disturbances%20in%20stimulant%20use%20disorders%2C...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fsleep-disturbances-stimulant-use-disorders-treatment-systematic-review%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[How common are sleep disturbances in patients with cocaine and methamphetamine use disorders?](#How_common_are_sleep_disturbances_in_patients_with_cocaine_and_methamphetamine_use_disorders) - [What pharmacological treatments show promise for sleep problems in stimulant use disorders?](#What_pharmacological_treatments_show_promise_for_sleep_problems_in_stimulant_use_disorders) - [Should sleep medications be prescribed differently for cocaine versus methamphetamine use disorders?](#Should_sleep_medications_be_prescribed_differently_for_cocaine_versus_methamphetamine_use_disorders) - [Are there safety concerns when prescribing sleep medications to patients with stimulant use disorders?](#Are_there_safety_concerns_when_prescribing_sleep_medications_to_patients_with_stimulant_use_disorders) - [How should clinicians measure sleep outcomes when treating patients with stimulant use disorders?](#How_should_clinicians_measure_sleep_outcomes_when_treating_patients_with_stimulant_use_disorders) - [Related](#Related) ## FAQ #### How common are sleep disturbances in patients with cocaine and methamphetamine use disorders? Sleep disturbances are highly prevalent in stimulant use disorders, affecting the majority of patients during both active use and withdrawal phases. These sleep problems can persist for weeks to months during recovery and significantly impact treatment outcomes and relapse risk. #### What pharmacological treatments show promise for sleep problems in stimulant use disorders? This systematic review identified 18 studies examining various pharmacological interventions, though the evidence base remains limited with only 678 total participants across all studies. The review found some promising options, but more robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are needed to establish clear treatment guidelines. #### Should sleep medications be prescribed differently for cocaine versus methamphetamine use disorders? The review included 11 studies in cocaine use disorder and 7 in methamphetamine use disorder, suggesting potential differences in treatment approaches. However, more research is needed to determine if specific medications work better for one stimulant versus another. #### Are there safety concerns when prescribing sleep medications to patients with stimulant use disorders? Prescribing sleep medications to patients with [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) requires careful consideration of abuse potential and [drug interactions](https://cedclinic.com/cannabis-liver-interactions-study-insights/). Clinicians should prioritize non-addictive options and closely monitor patients for misuse, especially given the complex neurochemical effects of stimulant withdrawal. #### How should clinicians measure sleep outcomes when treating patients with stimulant use disorders? The review only included studies using rigorous sleep measurement tools, emphasizing the importance of objective assessment methods. Clinicians should use validated sleep scales, sleep diaries, or consider sleep studies rather than relying solely on subjective patient reports to properly evaluate treatment effectiveness. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).